EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access

Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana‐Farber Cancer Institute ALL Consortium Study 16‐001

Alexandra Thrope, Sameera Ramjan iD, Charlie White, Audrey Mauguen, Lewis B Silverman, Jennifer J G Welch iD, Justine Kahn iD, Kara M Kelly, Thai-Hoa Tran, Bruno Michon, Lisa Gennarini, Yongkyu Park und 2 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70118 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Alexandra Thrope und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cognition, Executive Function, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, New Jersey Pediatric Hematology and Oncology Research Center of Excellence (NJ PHORCE) and by the Embrace Kids Foundation, National Institutes of Health/National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Children treated for acute lymphoblastic leukemia (ALL) are at risk of neurocognitive deficits in attention‐concentration, working memory, executive function, and psychomotor speed.

Objectives

This study evaluated longitudinal trajectories and medical/demographic associations with neurocognitive outcomes during treatment of newly diagnosed ALL.

Methods

Patients ages 3–21 treated on DFCI 16‐001 (NCT03020030) across eight North American sites (2017–2022) were evaluated using Cogstate across four timepoints from diagnosis through maintenance phase. Linear mixed models estimated trajectories and interactions with clinical factors over time, incorporating random effects for patients and sites.

Results

Among 298 patients (median age 7.9 years, 53% male), performance changed significantly over time in varying directions for executive functioning, attention, visual learning, and working memory‐accuracy (all p < 0.001). There was a significant interaction overall between age and time for psychomotor function (interaction p = 0.01) and working memory‐accuracy (interaction p < 0.001). Older age was associated with worse performance on working memory‐speed ( β = −0.04) and attention ( β = −0.05). Female sex was associated with worse performance on psychomotor function ( β = −0.27) and working memory‐accuracy ( β = −0.50), but better on visual learning ( β = 0.47) and working memory‐speed ( β = 0.30). A greater‐than‐expected proportion of participants performed below −1.5 SD on tests of attention, executive functioning, and psychomotor functioning at multiple timepoints.

Conclusions

While most patients demonstrated normal neurocognitive functioning, including variable trajectories, a subgroup performed poorly on attention, executive functioning, and psychomotor functioning. Risk factors include older age at diagnosis and female sex, which may provide insight into groups warranting early intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCognitionExecutive FunctionPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansMaleYoung AdultAttentionFollow-Up StudiesLongitudinal StudiesMemory, Short-TermNeuropsychological TestsPrognosisPsychomotor Performance

Stichwörter der Autor:innen

acute lymphoblastic leukemiacognitionneurocognitive outcomesrisk factors

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, New York, New York, USA.
  • Division of Pediatric Hematology/Oncology, Alpert School of Medicine, Brown University, Providence, Rhode Island, USA.
  • Department of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York, USA.

ORCID-Profile: Sameera Ramjan, Jennifer J G Welch, Justine Kahn, Peter D Cole, Stephen A Sands

Förderung

  • NCI NIH HHS
  • New Jersey Pediatric Hematology and Oncology Research Center of Excellence (NJ PHORCE) and by the Embrace Kids Foundation
  • National Institutes of Health/National Cancer Institute

Zitieren

APA

Thrope, A., Ramjan, S., White, C., Mauguen, A., Silverman, L. B., Welch, J. J. G., Kahn, J., Kelly, K. M., Tran, T. H., Michon, B., Gennarini, L., Park, Y., Cole, P. D., & Sands, S. A. (2026). Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana‐Farber Cancer Institute ALL Consortium Study 16‐001. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70118

Vancouver

Thrope A, Ramjan S, White C, Mauguen A, Silverman LB, Welch JJG, et al. Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana‐Farber Cancer Institute ALL Consortium Study 16‐001. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70118

BibTeX
@article{Thrope2026,
  author = {Thrope, Alexandra and Ramjan, Sameera and White, Charlie and Mauguen, Audrey and Silverman, Lewis B and Welch, Jennifer J G and Kahn, Justine and Kelly, Kara M and Tran, Thai-Hoa and Michon, Bruno and Gennarini, Lisa and Park, Yongkyu and Cole, Peter D and Sands, Stephen A},
  title = {Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana‐Farber Cancer Institute ALL Consortium Study 16‐001},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70118}
}
Kostenlos starten →